Project measures / variables set:   CSNA03   dist_f30_cont_do

ID, description, units MPD:90330   dist_f30_cont_do   distance traveled, first 30 min (pre-injection), on successive days, saline group, DO   [cm]  
Measures
• day:    • 1    • 2    • 3    • 5    • 7    • 9    • 11    • 12    • 19
Data set, strains CSNA03   DO population w/par   9 strains     sex: both     age: 8-21wks
Procedure open field test
Comparisontimecourse, same cohort
Ontology mappings

  SIDE-BY-SIDE STRAIN CURVES
Values
Graph Type
Dimensions Width:  ×  Height: px
Plot Options


  OVERLAPPING STRAIN CURVES
Data
Dimensions px
Toggle Series   
Plot Options
Advanced Plot Options
Separate Plot Factor(s)
Legend Factor(s)
X-Axis Factor(s)
Include/Exclude Factor Values

CSNA03 - distance traveled, first 30 min (pre-injection), on successive days, saline group, DO


  ANOVA, Q-Q NORMALITY ASSESSMENT

ANOVA Summary          "within" = Within error     "between" = Between Error (Animal ID)

Factor DF Sum of squares Mean sum of squares F value p-value (Pr>F)
within   day 8 928838472.675 116104809.0844 40.4226 < 0.0001
within   day:sex 8 38542677.9037 4817834.738 1.6774 0.0988
within   day:strain 64 644518753.5003 10070605.5234 3.5061 < 0.0001
within   day:sex:strain 64 475021631.8502 7422212.9977 2.5841 < 0.0001
within   Residuals 2776 7973438857.4494 2872276.2455
between   sex 1 349265653.7089 349265653.7089 5.4573 0.0201
between   strain 8 17493770866.8501 2186721358.3563 34.1676 < 0.0001
between   sex:strain 8 1340632009.1862 167579001.1483 2.6184 0.0086
between   Residuals 347 22207941662.96 63999831.8817

Q-Q normality assessment based on residuals

  


  INDIVIDUAL MEASURES
ProjectIDTreatmentMeasure / Variable Description PanelStrains
tested		SexAge
CSNA03 90330 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, DO   [cm]   day 1  dist_f30_cont_do_d1 DO population w/par 9 both 8-21wks
CSNA03 90336 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, DO   [cm]   day 2  dist_f30_cont_do_d2 DO population w/par 9 both 8-21wks
CSNA03 90342 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, DO   [cm]   day 3  dist_f30_cont_do_d3 DO population w/par 9 both 8-21wks
CSNA03 90348 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, DO   [cm]   day 5  dist_f30_cont_do_d5 DO population w/par 9 both 8-21wks
CSNA03 90354 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, DO   [cm]   day 7  dist_f30_cont_do_d7 DO population w/par 9 both 8-21wks
CSNA03 90360 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, DO   [cm]   day 9  dist_f30_cont_do_d9 DO population w/par 9 both 8-21wks
CSNA03 90366 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, DO   [cm]   day 11  dist_f30_cont_do_d11 DO population w/par 9 both 8-21wks
CSNA03 90372 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, DO   [cm]   day 12  dist_f30_cont_do_d12 DO population w/par 9 both 8-21wks
CSNA03 90378 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, DO   [cm]   day 19  dist_f30_cont_do_d19 DO population w/par 9 both 8-21wks



  •   Or, add these measures to your collection.
       
  •     no folder
  •     put them in new folder